Wednesday, June 19, 2024
EUROAPI has secured a five-year agreement with Priothera, a biotechnology company that specializes in treatments for blood cancers and enhancements in CAR-T cell therapies. Priothera operates out of Dublin, Ireland, with an additional branch in Saint-Louis, France.
As part of this partnership, EUROAPI will leverage its expertise in contract development and manufacturing to produce mocravimod, a novel oncology treatment. This development will take place at EUROAPI’s facility in Budapest, known for its proficiency in complex chemical processes.
EUROAPI CDMO, remarked, “Oncology is a significant area within our CDMO services. This partnership with Priothera demonstrates our capability to meet the needs of advanced innovation and maintain high standards of quality.” She also highlighted EUROAPI’s technological versatility and its capacity to respond to the growing demands in the industry.
Priothera, noted the importance of EUROAPI as a manufacturing partner, stating that this collaboration will expedite the development of mocravimod through an international Phase 3 clinical trial, with the goal of achieving regulatory approval and launching the treatment worldwide by 2027.
Mocravimod, which modulates the S1P 1 receptor, is being developed as both an adjunct and maintenance therapy for blood cancers to decrease relapse rates and improve survival rates among patients. The treatment is currently under investigation in a Phase 3 study involving approximately 250 adults with acute myeloid leukemia, spanning locations in the United States, Europe, Asia, and Latin America. The EMA and the US FDA have designated it as an orphan drug.
The global oncology market is growing, with expenditures on cancer treatments expected to reach $375 billion by 2027, up from $196 billion in 2022. The United States National Cancer Institute estimates that about 1.6% of individuals will be diagnosed with leukemia during their lifetime.
Source: globenewswire.com
